Obalon Therapeutics Inc (NASDAQ:OBLN) reached a new 52-week low on Monday . The stock traded as low as $2.01 and last traded at $2.01, with a volume of 57159 shares trading hands. The stock had previously closed at $2.20.
Several equities research analysts recently weighed in on the company. Zacks Investment Research lowered Obalon Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 11th. ValuEngine upgraded Obalon Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, July 4th. Stifel Nicolaus lowered Obalon Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 11th. Finally, Northland Securities lowered Obalon Therapeutics from a “market perform” rating to an “underperform” rating in a research report on Friday, May 11th. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $8.40.
Get Obalon Therapeutics alerts:The company has a quick ratio of 4.09, a current ratio of 4.29 and a debt-to-equity ratio of 0.29. The stock has a market cap of $35.32 million, a price-to-earnings ratio of -0.97 and a beta of -2.58.
Obalon Therapeutics (NASDAQ:OBLN) last issued its quarterly earnings data on Thursday, May 10th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.17). Obalon Therapeutics had a negative return on equity of 102.17% and a negative net margin of 399.94%. The company had revenue of $1.35 million for the quarter, compared to the consensus estimate of $3.55 million. equities analysts forecast that Obalon Therapeutics Inc will post -2.19 EPS for the current fiscal year.
A hedge fund recently bought a new stake in Obalon Therapeutics stock. Goldman Sachs Group Inc. acquired a new position in shares of Obalon Therapeutics Inc (NASDAQ:OBLN) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 237,647 shares of the company’s stock, valued at approximately $1,571,000. Goldman Sachs Group Inc. owned about 1.04% of Obalon Therapeutics as of its most recent SEC filing. 35.93% of the stock is currently owned by institutional investors and hedge funds.
About Obalon Therapeutics
Obalon Therapeutics, Inc, a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. It offers the Obalon balloon system designed to provide weight loss in obese patients. Obalon Therapeutics, Inc was founded in 2008 and is headquartered in Carlsbad, California.
Read More: Short Selling Stocks and Day Traders
No comments:
Post a Comment